Over a month ago
Downgrade
Guggenheim analyst Yatin…
Guggenheim analyst Yatin Suneja downgraded Sage Therapeutics to Neutral from Buy with no price target.
Show Hide Related Items >> <<
12/06/22 Sage Therapeutics, Biogen complete NDA to FDA for zuranolone 11/08/22 Sage sees cash and equivalents of $1.3B at end of FY22 11/01/22 Sage Therapeutics appoints Laura Gault, M.D. as Chief Medical Officer 10/17/22 Sage Therapeutics and Biogen present Phase 3 zuranolone results in depression 11/09/22 H.C. Wainwright Sage Therapeutics price target lowered to $50 from $55 at H.C. Wainwright 11/01/22 Loop Capital Sage Therapeutics initiated with a Hold at Loop Capital 08/03/22 Citi Sage Therapeutics price target lowered to $40 from $41 at Citi 08/02/22 Stifel Sage Therapeutics price target lowered to $56 from $58 at Stifel 11/08/22 Sage Therapeutics reports Q3 EPS ($2.31), consensus ($2.21) 08/02/22 Sage Therapeutics reports Q2 EPS ($2.13), consensus ($2.15)
Conference/Events
Investor luncheon meeting…
Investor luncheon meeting to be held in Boston on December 15 hosted by Piper Sandler.
Show Hide Related Items >> <<
12/06/22 Sage Therapeutics, Biogen complete NDA to FDA for zuranolone 11/08/22 Sage sees cash and equivalents of $1.3B at end of FY22 11/01/22 Sage Therapeutics appoints Laura Gault, M.D. as Chief Medical Officer 10/17/22 Sage Therapeutics and Biogen present Phase 3 zuranolone results in depression 11/09/22 H.C. Wainwright Sage Therapeutics price target lowered to $50 from $55 at H.C. Wainwright 11/01/22 Loop Capital Sage Therapeutics initiated with a Hold at Loop Capital 08/03/22 Citi Sage Therapeutics price target lowered to $40 from $41 at Citi 08/02/22 Stifel Sage Therapeutics price target lowered to $56 from $58 at Stifel 11/08/22 Sage Therapeutics reports Q3 EPS ($2.31), consensus ($2.21) 08/02/22 Sage Therapeutics reports Q2 EPS ($2.13), consensus ($2.15)
Conference/Events
Investor luncheon meeting…
Investor luncheon meeting to be held in Boston on December 15 hosted by Piper Sandler.
Show Hide Related Items >> <<
12/06/22 Sage Therapeutics, Biogen complete NDA to FDA for zuranolone 11/08/22 Sage sees cash and equivalents of $1.3B at end of FY22 11/01/22 Sage Therapeutics appoints Laura Gault, M.D. as Chief Medical Officer 10/17/22 Sage Therapeutics and Biogen present Phase 3 zuranolone results in depression 11/09/22 H.C. Wainwright Sage Therapeutics price target lowered to $50 from $55 at H.C. Wainwright 11/01/22 Loop Capital Sage Therapeutics initiated with a Hold at Loop Capital 08/03/22 Citi Sage Therapeutics price target lowered to $40 from $41 at Citi 08/02/22 Stifel Sage Therapeutics price target lowered to $56 from $58 at Stifel 11/08/22 Sage Therapeutics reports Q3 EPS ($2.31), consensus ($2.21) 08/02/22 Sage Therapeutics reports Q2 EPS ($2.13), consensus ($2.15)
Conference/Events
Biogen and Sage…
Biogen and Sage Therapeutics hold a joint investor webcast to discuss the planned commercialization approach and opportunity for their investigational product, Zuranolone, on December 6 at 8 am. Webcast Link
Show Hide Related Items >> <<
12/06/22 Sage Therapeutics, Biogen complete NDA to FDA for zuranolone 11/08/22 Sage sees cash and equivalents of $1.3B at end of FY22 11/01/22 Sage Therapeutics appoints Laura Gault, M.D. as Chief Medical Officer 10/17/22 Sage Therapeutics and Biogen present Phase 3 zuranolone results in depression 12/05/22 Biogen announces EMA accepted tofersen MAA to treat rare form of ALS 11/29/22 Eisai and Biogen present full results for Lecanemab phase 3 study in AD 11/10/22 Biogen names Viehbacher president, CEO 11/09/22 H.C. Wainwright Sage Therapeutics price target lowered to $50 from $55 at H.C. Wainwright 11/01/22 Loop Capital Sage Therapeutics initiated with a Hold at Loop Capital 08/03/22 Citi Sage Therapeutics price target lowered to $40 from $41 at Citi 08/02/22 Stifel Sage Therapeutics price target lowered to $56 from $58 at Stifel 12/02/22 JonesResearch Anavex price target raised to $80 from $40 at JonesTrading 12/01/22 Atlantic Equities Biogen price target raised to $295 from $220 at Atlantic Equities 11/30/22 Mizuho Mizuho says Biogen not mentioned in 90 minute lecanemab presentation 11/30/22 Jefferies Biogen price target raised to $350 from $325 at Jefferies 11/08/22 Sage Therapeutics reports Q3 EPS ($2.31), consensus ($2.21) 08/02/22 Sage Therapeutics reports Q2 EPS ($2.13), consensus ($2.15) 10/25/22 Biogen raises FY22 EPS view to $16.50-$17.15, consensus $16.49 10/25/22 Biogen reports Q3 adjusted EPS $4.77, consensus $4.15 10/24/22 Notable companies reporting before tomorrow's open 11/28/22 Second death linked to Eisai's lecanemab Alzheimer's drug, Science says 11/07/22 Biogen weighing new CEO options after talks with J&J exec hit impasse, STAT says 10/28/22 Investigator in Alzheimer's trial linked lecanemab to patient death, STAT says 10/07/22 Former J&J exec emerges as top candidate to become Biogen CEO, Statnews reports 11/30/22 Fly Intel: Pre-market Movers 11/28/22 Fly Intel: Pre-market Movers 11/14/22 What You Missed On Wall Street On Monday 11/14/22 What You Missed On Wall Street This Morning 11/30/22 Early notable gainers among liquid option names on November 30th 11/14/22 Early notable gainers among liquid option names on November 14th 10/13/22 Early notable gainers among liquid option names on October 13th 09/29/22 Unusually active option classes on open September 29th
Hot Stocks
Sage Therapeutics (SAGE)…
Sage Therapeutics (SAGE) and Biogen (BIIB) announced the completion of the rolling submission of a New Drug Application to the U.S. FDA for zuranolone in the treatment of major depressive disorder and postpartum depression. Zuranolone is an investigational drug being evaluated as a rapid-acting, once-daily, 14-day oral short course treatment in adults with MDD and PPD. The submission completes the NDA filing that was initiated earlier this year.
Show Hide Related Items >> <<
11/08/22 Sage sees cash and equivalents of $1.3B at end of FY22 11/01/22 Sage Therapeutics appoints Laura Gault, M.D. as Chief Medical Officer 10/17/22 Sage Therapeutics and Biogen present Phase 3 zuranolone results in depression 09/19/22 Sage Therapeutics, Biogen present analyses on efficacy, safety of zuranolone 12/05/22 Biogen announces EMA accepted tofersen MAA to treat rare form of ALS 11/29/22 Eisai and Biogen present full results for Lecanemab phase 3 study in AD 11/10/22 Biogen names Viehbacher president, CEO 10/17/22 Biogen announces FDA's 3-month expansion of review filing for NDA for tofersen 11/09/22 H.C. Wainwright Sage Therapeutics price target lowered to $50 from $55 at H.C. Wainwright 11/01/22 Loop Capital Sage Therapeutics initiated with a Hold at Loop Capital 08/03/22 Citi Sage Therapeutics price target lowered to $40 from $41 at Citi 08/02/22 Stifel Sage Therapeutics price target lowered to $56 from $58 at Stifel 12/02/22 JonesResearch Anavex price target raised to $80 from $40 at JonesTrading 12/01/22 Atlantic Equities Biogen price target raised to $295 from $220 at Atlantic Equities 11/30/22 Mizuho Mizuho says Biogen not mentioned in 90 minute lecanemab presentation 11/30/22 Jefferies Biogen price target raised to $350 from $325 at Jefferies 11/08/22 Sage Therapeutics reports Q3 EPS ($2.31), consensus ($2.21) 08/02/22 Sage Therapeutics reports Q2 EPS ($2.13), consensus ($2.15) 10/25/22 Biogen raises FY22 EPS view to $16.50-$17.15, consensus $16.49 10/25/22 Biogen reports Q3 adjusted EPS $4.77, consensus $4.15 10/24/22 Notable companies reporting before tomorrow's open 11/28/22 Second death linked to Eisai's lecanemab Alzheimer's drug, Science says 11/07/22 Biogen weighing new CEO options after talks with J&J exec hit impasse, STAT says 10/28/22 Investigator in Alzheimer's trial linked lecanemab to patient death, STAT says 10/07/22 Former J&J exec emerges as top candidate to become Biogen CEO, Statnews reports 11/30/22 Fly Intel: Pre-market Movers 11/28/22 Fly Intel: Pre-market Movers 11/14/22 What You Missed On Wall Street On Monday 11/14/22 What You Missed On Wall Street This Morning 11/30/22 Early notable gainers among liquid option names on November 30th 11/14/22 Early notable gainers among liquid option names on November 14th 10/13/22 Early notable gainers among liquid option names on October 13th 09/29/22 Unusually active option classes on open September 29th
Conference/Events
Biogen and Sage…
Biogen and Sage Therapeutics hold a joint investor webcast to discuss the planned commercialization approach and opportunity for their investigational product, Zuranolone, on December 6 at 8 am. Webcast Link
Show Hide Related Items >> <<
11/08/22 Sage sees cash and equivalents of $1.3B at end of FY22 11/01/22 Sage Therapeutics appoints Laura Gault, M.D. as Chief Medical Officer 10/17/22 Sage Therapeutics and Biogen present Phase 3 zuranolone results in depression 09/19/22 Sage Therapeutics, Biogen present analyses on efficacy, safety of zuranolone 12/05/22 Biogen announces EMA accepted tofersen MAA to treat rare form of ALS 11/29/22 Eisai and Biogen present full results for Lecanemab phase 3 study in AD 11/10/22 Biogen names Viehbacher president, CEO 10/17/22 Biogen announces FDA's 3-month expansion of review filing for NDA for tofersen 11/09/22 H.C. Wainwright Sage Therapeutics price target lowered to $50 from $55 at H.C. Wainwright 11/01/22 Loop Capital Sage Therapeutics initiated with a Hold at Loop Capital 08/03/22 Citi Sage Therapeutics price target lowered to $40 from $41 at Citi 08/02/22 Stifel Sage Therapeutics price target lowered to $56 from $58 at Stifel 12/02/22 JonesResearch Anavex price target raised to $80 from $40 at JonesTrading 12/01/22 Atlantic Equities Biogen price target raised to $295 from $220 at Atlantic Equities 11/30/22 Mizuho Mizuho says Biogen not mentioned in 90 minute lecanemab presentation 11/30/22 Jefferies Biogen price target raised to $350 from $325 at Jefferies 11/08/22 Sage Therapeutics reports Q3 EPS ($2.31), consensus ($2.21) 08/02/22 Sage Therapeutics reports Q2 EPS ($2.13), consensus ($2.15) 10/25/22 Biogen raises FY22 EPS view to $16.50-$17.15, consensus $16.49 10/25/22 Biogen reports Q3 adjusted EPS $4.77, consensus $4.15 10/24/22 Notable companies reporting before tomorrow's open 11/28/22 Second death linked to Eisai's lecanemab Alzheimer's drug, Science says 11/07/22 Biogen weighing new CEO options after talks with J&J exec hit impasse, STAT says 10/28/22 Investigator in Alzheimer's trial linked lecanemab to patient death, STAT says 10/07/22 Former J&J exec emerges as top candidate to become Biogen CEO, Statnews reports 11/30/22 Fly Intel: Pre-market Movers 11/28/22 Fly Intel: Pre-market Movers 11/14/22 What You Missed On Wall Street On Monday 11/14/22 What You Missed On Wall Street This Morning 11/30/22 Early notable gainers among liquid option names on November 30th 11/14/22 Early notable gainers among liquid option names on November 14th 10/13/22 Early notable gainers among liquid option names on October 13th 09/29/22 Unusually active option classes on open September 29th
Conference/Events
Biogen and Sage…
Biogen and Sage Therapeutics hold a joint investor webcast to discuss the planned commercialization approach and opportunity for their investigational product, Zuranolone, on December 6 at 8 am. Webcast Link
Show Hide Related Items >> <<
11/08/22 Sage sees cash and equivalents of $1.3B at end of FY22 11/01/22 Sage Therapeutics appoints Laura Gault, M.D. as Chief Medical Officer 10/17/22 Sage Therapeutics and Biogen present Phase 3 zuranolone results in depression 09/19/22 Sage Therapeutics, Biogen present analyses on efficacy, safety of zuranolone 12/05/22 Biogen announces EMA accepted tofersen MAA to treat rare form of ALS 11/29/22 Eisai and Biogen present full results for Lecanemab phase 3 study in AD 11/10/22 Biogen names Viehbacher president, CEO 10/17/22 Biogen announces FDA's 3-month expansion of review filing for NDA for tofersen 11/09/22 H.C. Wainwright Sage Therapeutics price target lowered to $50 from $55 at H.C. Wainwright 11/01/22 Loop Capital Sage Therapeutics initiated with a Hold at Loop Capital 08/03/22 Citi Sage Therapeutics price target lowered to $40 from $41 at Citi 08/02/22 Stifel Sage Therapeutics price target lowered to $56 from $58 at Stifel 12/02/22 JonesResearch Anavex price target raised to $80 from $40 at JonesTrading 12/01/22 Atlantic Equities Biogen price target raised to $295 from $220 at Atlantic Equities 11/30/22 Mizuho Mizuho says Biogen not mentioned in 90 minute lecanemab presentation 11/30/22 Jefferies Biogen price target raised to $350 from $325 at Jefferies 11/08/22 Sage Therapeutics reports Q3 EPS ($2.31), consensus ($2.21) 08/02/22 Sage Therapeutics reports Q2 EPS ($2.13), consensus ($2.15) 10/25/22 Biogen raises FY22 EPS view to $16.50-$17.15, consensus $16.49 10/25/22 Biogen reports Q3 adjusted EPS $4.77, consensus $4.15 10/24/22 Notable companies reporting before tomorrow's open 11/28/22 Second death linked to Eisai's lecanemab Alzheimer's drug, Science says 11/07/22 Biogen weighing new CEO options after talks with J&J exec hit impasse, STAT says 10/28/22 Investigator in Alzheimer's trial linked lecanemab to patient death, STAT says 10/07/22 Former J&J exec emerges as top candidate to become Biogen CEO, Statnews reports 11/30/22 Fly Intel: Pre-market Movers 11/28/22 Fly Intel: Pre-market Movers 11/14/22 What You Missed On Wall Street On Monday 11/14/22 What You Missed On Wall Street This Morning 11/30/22 Early notable gainers among liquid option names on November 30th 11/14/22 Early notable gainers among liquid option names on November 14th 10/13/22 Early notable gainers among liquid option names on October 13th 09/29/22 Unusually active option classes on open September 29th
Recommendations
H.C. Wainwright analyst…
H.C. Wainwright analyst Douglas Tsao lowered the firm's price target on Sage Therapeutics to $50 from $55 and keeps a Neutral rating on the shares post the Q3 results.
Show Hide Related Items >> <<
11/08/22 Sage sees cash and equivalents of $1.3B at end of FY22 11/01/22 Sage Therapeutics appoints Laura Gault, M.D. as Chief Medical Officer 10/17/22 Sage Therapeutics and Biogen present Phase 3 zuranolone results in depression 09/19/22 Sage Therapeutics, Biogen present analyses on efficacy, safety of zuranolone 11/01/22 Loop Capital Sage Therapeutics initiated with a Hold at Loop Capital 08/03/22 Citi Sage Therapeutics price target lowered to $40 from $41 at Citi 08/02/22 Stifel Sage Therapeutics price target lowered to $56 from $58 at Stifel 06/01/22 Piper Sandler Sage Therapeutics data better than Street expectations, says Piper Sandler 11/08/22 Sage Therapeutics reports Q3 EPS ($2.31), consensus ($2.21) 08/02/22 Sage Therapeutics reports Q2 EPS ($2.13), consensus ($2.15)
Hot Stocks
Sage anticipates cash,…
Sage anticipates cash, cash equivalents and marketable securities of approximately $1.3B at the end of 2022; does not anticipate receipt of any milestone payments from collaborations in 2022; anticipates R&D and SG&A spending to increase as it advances planned and ongoing studies for SAGE-718 and SAGE-324 and prepares for the potential launch of zuranolone; believes its cash and cash equivalents, anticipated funding from ongoing collaborations, and potential revenue, will support its operations into 2025.
Show Hide Related Items >> <<
11/01/22 Sage Therapeutics appoints Laura Gault, M.D. as Chief Medical Officer 10/17/22 Sage Therapeutics and Biogen present Phase 3 zuranolone results in depression 09/19/22 Sage Therapeutics, Biogen present analyses on efficacy, safety of zuranolone 06/13/22 Sage, Biogen to submit one zuranolone application for two indications 11/01/22 Loop Capital Sage Therapeutics initiated with a Hold at Loop Capital 08/03/22 Citi Sage Therapeutics price target lowered to $40 from $41 at Citi 08/02/22 Stifel Sage Therapeutics price target lowered to $56 from $58 at Stifel 06/01/22 Piper Sandler Sage Therapeutics data better than Street expectations, says Piper Sandler 11/08/22 Sage Therapeutics reports Q3 EPS ($2.31), consensus ($2.21) 08/02/22 Sage Therapeutics reports Q2 EPS ($2.13), consensus ($2.15)
Earnings
Reports Q3 revenue…
Reports Q3 revenue $1.74M, consensus $1.64M. Cash, cash equivalents and marketable securities as of September 30 were $1.4B compared to $1.5B at June 30. "This has been an important year for Sage, marked by the execution of significant milestones across our franchises. Looking ahead, we remain focused on the completion of the NDA submission for zuranolone in MDD and PPD, and are well into commercialization preparations to support a potential launch. Patients with depression are desperate to find new medicines that are safe, rapid-acting, short course, and have a sustained effect. We believe zuranolone, if approved, has the potential to deliver a new treatment option for patients," said Barry Greene, CEO. "In parallel, our team is advancing multiple clinical studies across our pipeline that span our neuropsychiatry and neurology franchises. I am proud of the tremendous progress our team has made on behalf of patients this year and am energized by the momentum we have going into 2023 and beyond."
Show Hide Related Items >> <<
11/01/22 Sage Therapeutics appoints Laura Gault, M.D. as Chief Medical Officer 10/17/22 Sage Therapeutics and Biogen present Phase 3 zuranolone results in depression 09/19/22 Sage Therapeutics, Biogen present analyses on efficacy, safety of zuranolone 06/13/22 Sage, Biogen to submit one zuranolone application for two indications 11/01/22 Loop Capital Sage Therapeutics initiated with a Hold at Loop Capital 08/03/22 Citi Sage Therapeutics price target lowered to $40 from $41 at Citi 08/02/22 Stifel Sage Therapeutics price target lowered to $56 from $58 at Stifel 06/01/22 Piper Sandler Sage Therapeutics data better than Street expectations, says Piper Sandler 08/02/22 Sage Therapeutics reports Q2 EPS ($2.13), consensus ($2.15)
